0000899243-22-003083.txt : 20220124 0000899243-22-003083.hdr.sgml : 20220124 20220124212721 ACCESSION NUMBER: 0000899243-22-003083 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220120 FILED AS OF DATE: 20220124 DATE AS OF CHANGE: 20220124 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: ENLOE J DAVID JR CENTRAL INDEX KEY: 0001201526 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36329 FILM NUMBER: 22550956 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Recro Pharma, Inc. CENTRAL INDEX KEY: 0001588972 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 261523233 STATE OF INCORPORATION: PA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1 E. UWCHLAN AVE, SUITE 112 CITY: EXTON STATE: PA ZIP: 19341 BUSINESS PHONE: 770-534-8239 MAIL ADDRESS: STREET 1: 1 E. UWCHLAN AVE, SUITE 112 CITY: EXTON STATE: PA ZIP: 19341 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-01-20 0 0001588972 Recro Pharma, Inc. REPH 0001201526 ENLOE J DAVID JR C/O RECRO PHARMA, INC. 1 E. UWCHLAN AVE, SUITE 112 EXTON PA 19341 1 1 0 0 Chief Executive Officer Common Stock 2022-01-20 4 A 0 66007 A 220766 D Common Stock 2022-01-20 4 A 0 303030 0.00 A 523796 D Stock Option (Right to Buy) 1.65 2022-01-20 4 A 0 442478 0.00 A 2032-01-20 Common Stock 442478 442478 D On January 20, 2022, the Compensation Committee of the Board of Directors of the Company determined that performance-vesting criteria were met with regard to 66,007 performance-based restricted stock units granted in a prior year, which were converted into 66,007 shares of common stock on a one-for-one basis. These restricted stock units will vest in four equal annual installments beginning on January 20, 2023, subject to continued service with the Company. The stock option vests in equal monthly installments over 48 months, beginning on February 20, 2022, subject to continued service with the Company. By: Ryan D Lake, attorney-in-fact 2022-01-24